Table 1. Characteristics of patients with concurrent EGFR and ALK alterations.

*=not reported, ¹Secondary mutation on crizitonib, NT=not treated, GNC=gene copy number

Citation	Age	Sex	Smoking	Stage	EGFR Alteration	EGFR-TKI		ALK Variant	ALK-TKI
						Response	Months		Response	Months
16	72	F	Never	IV	Exon19 deletion	PR	7	1	NT
12	65	F	Never	IV	Exon19 deletion	CR	25	*	NT
13	48	M	Never	IV	Exon19 deletion	PD	2	*	NT
18	*	F	Never	*	Exon19 deletion	*		3b	NT
15	39	M	Light	IV	L858R	PD	1	3b	NT
10	55	F	Never	IV	Exon19 deletion	SD	3	2	SD	4
9	77	F	Never	*	L861Q	PD	2	↑GCN	SD	4
11	*	*	*	*	Exon19 deletion	*		*	*
14	*	*	*	*	L858R	PR	9	*	*
14	*	*	*	*	Exon19 deletion	PR	5+	*	*
14	*	*	*	*	A767_V769dupASV	NT		*	*
17	73	M	15 p/y	IV	Exon19 deletion	PD	<1	*	PR	9+
17	*	*	*	IIB	Exon19 deletion	NT		*	NT
17	*	*	*	IIIA	L718P	NT		*	NT
17	*	*	*	IA	L858R	NT		*	NT
21	61	M	Never	IV	L862R1	NT		*	PR	8
Case 1	37	M	Never	IV	Exon23 polymorphism	PR	12	*	SD	9
Case 2	57	F	15 p/y	IV	L861Q	PR	2	*	NT	-
Case 3	66	F	Never	IV	Exon19 deletion	PD	2	*	PD	1
Case 4	52	M	30 p/y	IV	L858R	PD	2	*	PD	<1